Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

被引:31
作者
Caputo, A
Brocca-Cofano, E
Castaldello, A
De Michele, R
Altavilla, G
Marchisio, M
Gavioli, R
Rolen, U
Chiarantini, L
Cerasi, A
Dominici, S
Magnani, M
Cafaro, A
Sparnacci, K
Laus, M
Tondelli, L
Ensoli, B
机构
[1] Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, I-44100 Ferrara, Italy
[2] Univ Padua, Inst Pathol Anat & Histol, I-35100 Padua, Italy
[3] Univ Ferrara, Dept Morphol & Embryol, I-44100 Ferrara, Italy
[4] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
[5] Univ Urbino, Dept Biochem, I-61029 Urbino, Italy
[6] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy
[7] Univ Piemonte Orientale, Dept Adv Sci & Technol, I-15100 Alessandria, Italy
[8] UdR, INSTM, I-15100 Alessandria, Italy
[9] CNR, ISOF, I-40129 Bologna, Italy
关键词
biocompatible microspheres; HIV-1 Tat protein; vaccine;
D O I
10.1016/j.vaccine.2003.12.025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two novel classes of biocompatible core-shell anionic microspheres, composed of an inner hard insoluble core, either made of poly(styrene) (PS) or poly(methyl methacrylate) (PMMA), and a soft outer tentacular shell made of long soluble negatively charged arms derived from the steric stabilizer, hemisuccinated poly(vinyl alcohol) or Eudragit L100/55, respectively, were prepared by dispersion polymerization and characterized. Five types of these novel microspheres, two made of poly(styrene) and hemisuccinated poly(vinyl alcohol) (A4 and A7), and three made of poly(methyl methacrylate) and Eudragit L100/55 (1D, 1E, H1D), differing for chemical composition, size, and surface charge density were analyzed for the delivery of the HIV-1 Tat protein for vaccine applications. All microspheres reversibly adsorbed the native biologically active HIV-1 Tat protein preventing Tat from oxidation and maintaining its biological activity, therefore increasing the shelf-life of the Tat protein vaccine. The microspheres efficiently delivered Tat intracellularly, and were not toxic in vitro nor in mice, even after multiple administrations. These results indicate that these novel microparticles are safe and represent a promising delivery system for vaccination with Tat, as well as for other subunit vaccines, particularly when a native protein conformation is required. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2910 / 2924
页数:15
相关论文
共 74 条
[1]   CONTROLLED-RELEASE VACCINES - BIODEGRADABLE POLYLACTIDE POLYGLYCOLIDE (PL/PG) MICROSPHERES AS ANTIGEN VEHICLES [J].
AGUADO, MT ;
LAMBERT, PH .
IMMUNOBIOLOGY, 1992, 184 (2-3) :113-125
[2]   A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice [J].
Agwale, SM ;
Shata, MT ;
Reitz, MS ;
Kalyanaraman, VS ;
Gallo, RC ;
Popovic, M ;
Hone, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :10037-10041
[3]   Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres [J].
Allaoui-Attarki, K ;
Fattal, E ;
Pecquet, S ;
Trollé, S ;
Chachaty, E ;
Couvreur, P ;
Andremont, A .
VACCINE, 1998, 16 (07) :685-691
[4]  
Alpar HO, 2000, STP PHARMA SCI, V10, P269
[5]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[6]   Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats:: modification of the body distribution after suspension in surfactant solutions and in oil vehicles [J].
Araujo, L ;
Sheppard, M ;
Löbenberg, R ;
Kreuter, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 176 (02) :209-224
[7]  
Arthur JF, 1997, CANCER GENE THER, V4, P17
[8]   TRANS-ACTIVATOR GENE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-III (HTLV-III) [J].
ARYA, SK ;
GUO, C ;
JOSEPHS, SF ;
WONGSTAAL, F .
SCIENCE, 1985, 229 (4708) :69-73
[9]   Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application [J].
Betti, M ;
Voltan, R ;
Marchisio, M ;
Mantovani, I ;
Boarini, C ;
Nappi, F ;
Ensoli, B ;
Caputo, A .
VACCINE, 2001, 19 (25-26) :3408-3419
[10]   Interaction of Serum Components with Poly(methylmethacrylate) Nanoparticles and the Resulting Body Distribution after Intravenous Injection in Rats [J].
Borchard, G. ;
Kreuter, J. .
JOURNAL OF DRUG TARGETING, 1993, 1 (01) :15-19